Difference between revisions of "SMARCA4-deficient non-small cell carcinoma of the lung"
Jump to navigation
Jump to search
(→IHC) |
|||
| Line 1: | Line 1: | ||
'''SMARCA4-deficient adenocarcinoma of the lung''' is an emerging subtype of [[lung adenocarcinoma]].<ref name=pmid28555282>{{Cite journal | last1 = Agaimy | first1 = A. | last2 = Fuchs | first2 = F. | last3 = Moskalev | first3 = EA. | last4 = Sirbu | first4 = H. | last5 = Hartmann | first5 = A. | last6 = Haller | first6 = F. | title = SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1 | journal = Virchows Arch | volume = 471 | issue = 5 | pages = 599-609 | month = Nov | year = 2017 | doi = 10.1007/s00428-017-2148-5 | PMID = 28555282 }}</ref> | '''SMARCA4-deficient adenocarcinoma of the lung''' is an emerging subtype of [[lung adenocarcinoma]].<ref name=pmid28555282>{{Cite journal | last1 = Agaimy | first1 = A. | last2 = Fuchs | first2 = F. | last3 = Moskalev | first3 = EA. | last4 = Sirbu | first4 = H. | last5 = Hartmann | first5 = A. | last6 = Haller | first6 = F. | title = SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1 | journal = Virchows Arch | volume = 471 | issue = 5 | pages = 599-609 | month = Nov | year = 2017 | doi = 10.1007/s00428-017-2148-5 | PMID = 28555282 }}</ref> | ||
==General== | |||
*~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.<ref name=pmid28038711>{{Cite journal | last1 = Herpel | first1 = E. | last2 = Rieker | first2 = RJ. | last3 = Dienemann | first3 = H. | last4 = Muley | first4 = T. | last5 = Meister | first5 = M. | last6 = Hartmann | first6 = A. | last7 = Warth | first7 = A. | last8 = Agaimy | first8 = A. | title = SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. | journal = Ann Diagn Pathol | volume = 26 | issue = | pages = 47-51 | month = Feb | year = 2017 | doi = 10.1016/j.anndiagpath.2016.10.006 | PMID = 28038711 }}</ref> | |||
==IHC== | ==IHC== | ||
| Line 6: | Line 9: | ||
*TTF-1 -ve. | *TTF-1 -ve. | ||
*HepPar-1 +ve. | *HepPar-1 +ve. | ||
*SMARCA4 -ve. | |||
==See also== | ==See also== | ||
Revision as of 20:53, 14 November 2018
SMARCA4-deficient adenocarcinoma of the lung is an emerging subtype of lung adenocarcinoma.[1]
General
- ~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.[2]
IHC
Features:[1]
- CK7 +ve.
- TTF-1 -ve.
- HepPar-1 +ve.
- SMARCA4 -ve.
See also
References
- ↑ 1.0 1.1 Agaimy, A.; Fuchs, F.; Moskalev, EA.; Sirbu, H.; Hartmann, A.; Haller, F. (Nov 2017). "SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1". Virchows Arch 471 (5): 599-609. doi:10.1007/s00428-017-2148-5. PMID 28555282.
- ↑ Herpel, E.; Rieker, RJ.; Dienemann, H.; Muley, T.; Meister, M.; Hartmann, A.; Warth, A.; Agaimy, A. (Feb 2017). "SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.". Ann Diagn Pathol 26: 47-51. doi:10.1016/j.anndiagpath.2016.10.006. PMID 28038711.